Patients with COVID-19 will be restricted to telehealth consultations with their regular practice from 1 July after Medicare scraps their exemption to the existing relationship…
The TGA has withdrawn approval for COVID-19 vaccine Vaxzevria on the request of its sponsor, AstraZeneca. It finally closes a complex and controversial chapter in…
Nirmatrelvir-ritonavir is no better than placebo for resolving symptoms in patients who are at low risk for severe COVID-19, results from an international study suggest.…
Patients with acute hypoxaemic respiratory failure who receive oxygen via a helmet interface likely have better survival rates than those given standard oxygen therapy, a…
Molnupiravir may cut the risk of long COVID symptoms as well as post-acute death, regardless of a patient’s vaccination status or prior infection, US epidemiologists…
Leading doctors have clashed over eligibility criteria for COVID-19 antivirals — specifically nirmatrelvir–ritonavir — following claims many patients were being “short-changed” and left unprotected. Federal…
Nirmatrelvir–ritonavir halves the risk of death and hospitalisation in patients with mild COVID-19 at risk of severe disease — even during the Omicron variant era…
A new oral antiviral might be more favourable than nirmatrelvir–ritonavir in shortening recovery times for at-risk adults with COVID-19, a study suggests. The China-based phase…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
